Table 1. Clinical efficacy of targeted environmental drugs in chronic lymphocytic leukemia.

Agent	Current status	Target	Nodal decrease > 50%	Response rate by 2008 IW-CLL criteria
AMD310034	Under clinic phase II	Inhibiting CXCL12/CXCR4 axis	-	36%
GS-110150	Under clinic phase III	Inhibiting PI3K signaling	91%	33%
Ibrutinib57	Under clinic phase III	Inhibiting BTK signaling	87%	79%
Fostamatinib63	Under clinic phase II	Inhibiting SYN signaling	63%	55%
Lenalidomide68	Complete clinic phase II	Increasing bFGF and VEGF secretion; inhibiting PI3K signaling	50%	56%
Sorafenib71	In malignant B cell lines	Blocking phosphorylation of ERK and MEK	-	-
Dasatinib75	Complete clinic phase II	Inhibit BCR signaling	44.4%	20%

IW-CLL, International Workshop on Chronic Lymphocytic Leukemia; -, not provided